← Eichor
Condition: Myasthenia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myasthenia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Phase N/A · 23 location(s) · Alexion Pharmaceuticals, Inc. · NCT06967480Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Phase N/A · 12 location(s) · AstraZeneca · NCT06909253Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myast
Phase 3 · 145 location(s) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of M · NCT06463587The EXPLORE MG Registry for Myasthenia Gravis
Phase N/A · 1 location(s) · Yale University · NCT03792659Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT07022197Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
Phase N/A · 1 location(s) · Institut de Myologie, France · NCT06866652A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 9 location(s) · UCB Biopharma SRL · NCT06055959Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
Phase N/A · 4 location(s) · Huashan Hospital · NCT04535843Collection of Biological Samples From Patients With Rare Neurological Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT04698421ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With
Phase 2 · 15 location(s) · argenx · NCT07284420FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-m
Phase N/A · 1 location(s) · ZS Associates · NCT06866483Myasthenia Gravis Registry in China
Phase N/A · 16 location(s) · Huashan Hospital · NCT06241521A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Disease
Phase 1 · 13 location(s) · Arcellx, Inc. · NCT06626919Study of Myasthenic Crisis in China
Phase N/A · 1 location(s) · Huashan Hospital · NCT04837625Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
NA · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07413835A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 19 location(s) · Janssen Research & Development, LLC · NCT05265273Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Phase 1/Phase 2 · 3 location(s) · Aurinia Pharmaceuticals Inc. · NCT07596901PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3 · 13 location(s) · Alexion Pharmaceuticals, Inc. · NCT06607627Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1/Phase 2 · 11 location(s) · Novartis Pharmaceuticals · NCT06704269Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Phase N/A · 1 location(s) · Brain Inflammation Collaborative · NCT04806620A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Gener
Phase 3 · 129 location(s) · Novartis Pharmaceuticals · NCT06744920Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni
Phase 4 · 12 location(s) · UCB Biopharma SRL · NCT07246564Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Phase 3 · 34 location(s) · Cartesian Therapeutics · NCT06799247Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Phase N/A · 51 location(s) · Alexion Pharmaceuticals, Inc. · NCT04202341Vitaccess Real MG Registry
Phase N/A · 8 location(s) · Vitaccess Ltd · NCT06064461A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administrat
Phase 2 · 2 location(s) · TG Therapeutics, Inc. · NCT07673744A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Phase 2 · 24 location(s) · Vertex Pharmaceuticals Incorporated · NCT07501702
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.